Skip to main content

Omitting 5-FU Bolus Does Not Reduce Survival in Advanced Cancer

Medically reviewed by Carmen Pope, BPharm. Last updated on Sep 11, 2024.

By Elana Gotkine HealthDay Reporter

TUESDAY, Sept. 10, 2024 -- Omission of 5-fluorouracil (5-FU) from the first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens is not associated with reduced survival among patients with advanced colorectal, gastroesophageal, and pancreatic cancers, according to a study published online Sept. 5 in the Journal of the National Comprehensive Cancer Network.

Chengwei Peng, M.D., from New York University in New York City, and colleagues queried a real-world database for patients with advanced colorectal, gastroesophageal, and pancreatic cancers (8,670, 1,481, and 1,614 patients, respectively) who received first-line FOLFOX, FOLFIRI, and FOLFIRINOX regimens to examine whether omission of the 5-FU bolus is associated with a difference in survival and toxicity.

Overall, 86.3 and 13.7 percent of patients received and did not receive a 5-FU bolus, respectively. The researchers found that omitting the bolus was not associated with a reduction in overall survival after inverse probability of treatment-weighted analysis. However, there were significant associations for bolus omission with reductions in neutropenia (10.7 versus 22.7 percent), thrombocytopenia (11.2 versus 16.1 percent), and use of granulocyte colony-stimulating factor (19.6 versus 29.1 percent) after treatment.

"Our data suggest that omitting the 5-FU bolus may lead to reduced treatment toxicity without compromising efficacy. Future prospective studies are needed to confirm these findings, especially applicability to the adjuvant setting," the authors write.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)2fjnccnAbstract/Full Text (subscription or payment may be required)2faopAbstract/Full Text (subscription or payment may be required)2farticle-10.6004-jnccn.2024.7029Abstract/Full Text (subscription or payment may be required)2farticle-10.6004-jnccn.2024.7029.xml?t:ac=journals%24002fjnccn%24002faop%24002farticle-10.6004-jnccn.2024.7029%24002farticle-10.6004-jnccn.2024.7029.xml">Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted September 2024

Read this next

AI Can Use ECG Images to Define Risk for Cancer Therapy-Linked Cardiac Dysfunction

MONDAY, Sept. 16, 2024 -- For patients undergoing treatment for certain types of cancer, artificial intelligence (AI) can use electrocardiographic (ECG) images to define the risk...

Long-Course Chemoradiotherapy Preferred TNT Regimen for Rectal Cancer

THURSDAY, Sept. 12, 2024 -- For patients with locally advanced rectal cancer pursuing organ preservation, long-course chemoradiotherapy (LCCRT) is the preferred total neoadjuvant...

Risk for Second Primary Cancer May Be No Higher With CAR T-Cell Versus Standard of Care

THURSDAY, Sept. 12, 2024 -- The overall second primary malignancy (SPM) point estimate was 5.8 percent for patients receiving chimeric antigen receptor (CAR) T-cell therapy...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.